M 943 (Divalproex Sodium Delayed-Release 125 mg)
Pill with imprint M 943 is Blue, Round and has been identified as Divalproex sodium delayed-release 125 mg. It is supplied by Mylan Pharmaceuticals Inc..
Divalproex sodium is used in the treatment of bipolar disorder; migraine prevention; mania; borderline personality disorder; epilepsy (and more), and belongs to the drug class fatty acid derivative anticonvulsants. When treating epilepsy and manic episodes associated with bipolar disorder: There is positive evidence of human fetal risk during pregnancy. When treating migraine: Not for use in pregnancy. Divalproex sodium 125 mg is not a controlled substance under the Controlled Substance Act (CSA).
Images for M 943
- M 943
- 125 mg
- 9.00 mm
- Prescription only
- Drug Class:
- Fatty acid derivative anticonvulsants
- Pregnancy Category:
- D - Positive evidence of risk - When treating epilepsy and manic episodes associated with bipolar disorder
X - Not for use in pregnancy - When treating migraine
- CSA Schedule:
- Not a controlled drug
- Labeler / Supplier:
- Mylan Pharmaceuticals Inc.
- Inactive Ingredients:
- ferrosoferric oxide
FD&C Blue No. 2
FD&C Yellow No. 6
methacrylic acid - ethyl acrylate copolymer (1:1) type a
Note: Inactive ingredients may vary.
More about divalproex sodium
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 318 Reviews – Add your own review/rating
- Drug class: fatty acid derivative anticonvulsants
- Divalproex sodium
- Divalproex Long-Acting Tablets
- Divalproex Sprinkle Capsules
- Divalproex sodium (Advanced Reading)
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2018 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.